Kinoxis Therapeutics is a biotechnology company that develops a range of novel therapeutic compounds.
Kinoxis Therapeutics has raised $4.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2026.
Kinoxis Therapeutics's investors include Main Sequence Ventures, National Institutes of Health, Uniseed, University of Sydney, Stoic VC.
Kinoxis Therapeutics is headquartered in Melbourne, Australia.
Kinoxis Therapeutics is a biotechnology company that develops a range of novel therapeutic compounds.
Kinoxis Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kinoxis Therapeutics — Funding & Investors." VCBacked, September 22, 2026, https://www.vcbacked.co/company/kinoxis-therapeutics. Accessed October 19, 2026.
VCBacked. (2026). Kinoxis Therapeutics — Funding & Investors. Retrieved October 19, 2026, from https://www.vcbacked.co/company/kinoxis-therapeutics
{{cite web |title=Kinoxis Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kinoxis-therapeutics |website=VCBacked |access-date=October 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated